Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov-Dec;25(6):527-531.
doi: 10.4103/ijem.ijem_333_21. Epub 2022 Feb 17.

Evaluation of Hypersensitivity Reactions with Leuprolide Acetate and Triptorelin Acetate in Children

Azize Pınar Metbulut  1 , Keziban Toksoy Adıgüzel  2 , Candan İslamoğlu  1 , Mehmet Boyraz  2   3 , Emine Dibek Mısırlıoğlu  1
Affiliations

Evaluation of Hypersensitivity Reactions with Leuprolide Acetate and Triptorelin Acetate in Children

Azize Pınar Metbulut et al. Indian J Endocrinol Metab. 2021 Nov-Dec.

Abstract

Introduction: Gonadotropin releasing hormone analogues (GnRHa) are commonly used to treat central precocious puberty (CPP). Generally, they are well-tolerated; however adverse reactions have been reported. Local adverse events occur in 10-15% of the patients who were treated with GnRHa. Anaphylactoid reactions with GnRHa are very rarely seen. The aim of this study is to report our clinical experience with hypersensitivity reactions seen in pediatric patients receiving leuprolide acetate (LA) and triptorelin acetate (TA) in CPP at the single pediatric tertiary medical center and to evaluate the incidence rate of hypersensitivity reactions.

Methods: This retrospective study included children with CPP who were treated with GnRHa (LA and TA) at our hospital between January 2013 and December 2020. We analyzed clinical characteristics of patients who experienced adverse reactions and analyzed the incidence rate.

Results: Seven side effects (adverse reactions) (0.69%) were observed among total of 1010 CPP patients who were treated with TA and LA. Sterile abscesses were observed in 3 patients (0.29%). None of the patients had an anaphylaxis. Tremors of both hands, a vomiting episode, an urticarial rash, and musculoskeletal stiffness were observed in one patient each.

Conclusion: In our study, mild reactions were seen in 7 patients. GnRHa can be safely used and well-tolerated medications; but exceedingly rare, severe reactions can be developed.

Keywords: Adverse reactions; central precocious puberty; drug hypersensitivity reaction; gonadotropin-releasing hormone analogues.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

References

    1. Wilson AC, Meethal SV, Bowen RL, Atwood CS. Leuprolide acetate: A drug of diverse clinical applications. Expert Opin Investig Drugs. 2007;16:1851–63. - PubMed
    1. Fujisaki A, Kondo Y, Goto K, Morita T. Life-threatening anaphylaxis to leuprorelin acetate depot: Case report and review of the literature. Int J Urol. 2012;19:81–4. - PubMed
    1. Gnanaraj J, Saif MW. Hypersensitivity vasculitis associated with leuprolide (Lupron) Cutan Ocul Toxicol. 2010;29:224–7. - PubMed
    1. Lee JW, Kim HJ, Choe YM, Kang HS, Kim SK, Jun YH, et al. Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty. Ann Pediatr Endocrinol Metab. 2014;19:135–40. - PMC - PubMed
    1. Dona I, Salas M, Perez-Sanchez NI, Aguilar C, Torres MJ. Phenotypes and natural evolution of drug hypersensitivity. Curr Treat Options Allergy. 2019;6:27–41.